Vira Health’s core product is Stella, a personalized menopause app that launched in the U.K. in August and delivers tailored 12-week programs combining exercise, diet advice, cognitive behavioral therapy and pelvic-floor interventions based on users’ reported symptoms. The app also offers community features such as expert Q&As and group sessions. Today Stella is offered as an information service rather than a regulated medical device, though Vira plans to add a telehealth component to enable virtual physician consultations and prescriptions and may seek regulatory clearance as the product evolves. The company is preparing a U.S. launch in the second half of the year and will adapt content and localization for the market. Vira’s business model combines direct-to-consumer subscriptions with a B2B2C employer-benefit channel. The company is also funding clinical trials and cites a December–February feasibility study suggesting 75% of women who completed Stella treatment plans experienced improved symptoms. Vira Health, founded in 2020 by Andrea Berchowitz and Rebecca Love, builds personalized menopause care delivered via its Stella app. Stella highlights 12-week menopause treatment plans, content and virtual events including yoga classes and Q&As with gynecologists. The company positions itself to improve collection and use of female health data and to address historical underinvestment in female health. Vira raised its first institutional funding — a seed round — to advance that vision. Co-founder Andrea Berchowitz previously worked at McKinsey and led Middle East operations for the Bill and Melinda Gates Foundation, bringing womens’ health experience across public and private sectors. The seed raise is presented as a step toward scaling the product and capturing data insights to reshape care delivery.

Total raised

$14M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2022